March 14, 2018 / 11:18 AM / 7 months ago

BRIEF-Valeant Receives Health Canada Approval Of Siliq (Brodalumab) For Moderate-To-Severe Plaque Psoriasis

March 14 (Reuters) - Valeant Pharmaceuticals International Inc:

* VALEANT RECEIVES HEALTH CANADA APPROVAL OF SILIQ (BRODALUMAB) FOR MODERATE-TO-SEVERE PLAQUE PSORIASIS

* VALEANT CANADA SAYS EXPECTS TO COMMENCE SALES AND MARKETING OF SILIQ IN THE CANADA IN THE SECOND HALF OF 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below